CBD and Huntington’s Disease

Peer-reviewed studies into the potential effects of Cannabidiol and Huntington’s Disease

On this page, CBD and Huntington’s Disease, you will find research pertaining to the use of Cannabidiol and Cannabinoids and its possible effects on Huntington’s Disease The information below is not meant to influence your opinion, but rather give you access to a wealth of scientific literature in an attempt to make and educated and informed choice. Click Here to see all of the conditions that have been researched alongside CBD and Huntington’s Disease. If you have any questions pertaining to the research, please email us at info@hempicated.com.

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease.

From the abstract:

In conclusion, this study provides preclinical evidence in support of a beneficial effect of the cannabis-based medicine Sativex as a neuroprotective Agent Capable of delaying disease progression in [Huntington’s Disease], a disorder that is currently poorly managed in the clinic, prompting an urgent need for clinical trials with agents showing positive results in preclinical studies

Cannabinoids: novel medicines for the treatment of Huntington’s disease. 

From the abstract:

Cannabinoids have been studied for alleviation of hyperkinetic symptoms, given their inhibitory effects on movement, and, in particular, as disease-modifying agents due to their anti-inflammatory, neuroprotective and neuroregenerative properties. This potential has been corroborated in different experimental models of [Huntington’s Disease] and using different types of cannabinoid agonists, including the phytocannabinoids present in Sativex…

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors  

From the abstract:

In summary, this study provides preclinical evidence in support of a beneficial effect of the cannabis-based medicine Sativex as a neuroprotective agent capable of delaying signs of disease progression in a proinflammatory model of [Huntington’s Disease], which adds to previous data obtained in models priming oxidative mechanisms of striatal injury. 

Prospects for cannabinoid therapies in basal ganglia disorders.

From the abstract:

… the evidence reported so far supports that those cannabinoids having antioxidant properties and/or capability to activate CB(2) receptors may represent promising therapeutic agents in [Huntington’s Disease] and [Parkinson’s Disease]…

Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

From the abstract:

Different plant-derived and synthetic cannabinoids have shown to be neuroprotective in experimental models of Huntington’s disease (HD) through cannabinoid receptor-dependent and/or independant mechanisms. … [cannabigerol] was extremely active as a neuroprotectant in mice intoxicated with 3-nitropropionate (3NP), improving motor deficits and preserving striatal neurons against 3NP toxicity. In addition, CBG attenuated the reactive microgliosis and the upregulation of proinflammatory markers induced by 3NP, and improved the levels of antioxidant defenses that were also significantly reduced by 3NP.

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease.

From the abstract:

A Sativex-like combination of phytocannabinoids administered to R6/2 mice at the onset of motor symptoms produced certain benefits on the progression of striatal deterioration in these mice, which supports the interest of this cannabinoid-based medicine for the treatment of disease progression in [Huntington’s Disease] patients.